| Keywords: |
cancer survival; treatment outcome; aged; middle aged; survival analysis; cancer surgery; clinical trial; drug efficacy; cancer adjuvant therapy; neoadjuvant therapy; follow-up studies; neoplasm staging; ki 67 antigen; ki-67 antigen; biological marker; breast cancer; drug administration schedule; epidermal growth factor receptor 2; tumor markers, biological; aromatase inhibitor; dose-response relationship, drug; breast neoplasms; risk assessment; cancer hormone therapy; statistical analysis; needle biopsy; drug response; reference values; tamoxifen; outcomes research; short survey; receptor, erbb-2; letrozole; preoperative treatment; antineoplastic agents, hormonal; estrogen receptor; progesterone receptor; anastrozole; double-blind method; postmenopause; triazoles; nitriles; mastectomy, segmental; her2; neoplasms, hormone-dependent; biomaker; homornal therapy
|
